Abstract
Kinetic parameters describing hepatic uptake in hepatocytes are frequently estimated without appropriate incorporation of bidirectional passive diffusion, intracellular binding, and metabolism. A mechanistic two-compartment model was developed to describe all of the processes occurring during the in vitro uptake experiments performed in freshly isolated rat hepatocytes plated for 2 h. Uptake of rosuvastatin, pravastatin, pitavastatin, valsartan, bosentan, telmisartan, and repaglinide was investigated over a 0.1 to 300 μM concentration range at 37°C for 2 or 45–90 min; nonspecific binding was taken into account. All concentration-time points were analyzed simultaneously by using a mechanistic two-compartment model describing uptake kinetics [unbound affinity constant (Km,u), maximum uptake rate (Vmax), unbound active uptake clearance (CLactive,u)], passive diffusion [unbound passive diffusion clearance (Pdiff,u)], and intracellular binding [intracellular unbound fraction (fucell)]. When required (telmisartan and repaglinide), the model was extended to account for the metabolism [unbound metabolic clearance (CLmet,u)]. The CLactive,u ranged 8-fold, reflecting a 11-fold range in uptake Km,u, with telmisartan and valsartan showing the highest affinity for uptake transporters (Km,u <10 μM). Both Pdiff,u and fucell span over two orders of magnitude and reflected the lipophilicity of the drugs in the dataset. An extended incubation time allowed steady state to be reached between media and intracellular compartment concentrations and reduced the error in certain parameter estimates observed with shorter incubation times. Active transport accounted for >70% of total uptake for all drugs investigated and was 4- and 112-fold greater than CLmet,u for telmisartan and repaglinide, respectively. Modeling of uptake kinetics in conjunction with metabolism improved the precision of the uptake parameter estimates for repaglinide and telmisartan. Recommendations are made for uptake experimental design and modeling strategies.
Footnotes
K.M. was supported by a Ph.D studentship from GlaxoSmithKline, Ware, UK and the Biotechnology and Biological Sciences Research Council of the United Kingdom.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- NCE
- new chemical entity
- OATP
- organic anion-transporting protein
- ABT
- 1-aminobenzotriazole
- M1
- 2-despiperidyl-2-amino repaglinide
- M2
- 2-despiperidyl-2(5-carboxypentylamine) repaglinide
- M4
- 3′-hydroxy repaglinide
- fumed
- unbound fraction in the media
- fucell
- intracellular unbound fraction
- Pdiff
- passive diffusion clearance
- Pdiff,u
- unbound passive diffusion clearance
- Km,u
- unbound affinity constant
- Vmax
- maximum uptake rate
- CLactive,u
- unbound active uptake clearance
- CLuptake,u
- unbound total uptake clearance
- CLmet,u
- unbound metabolic clearance
- CLmet,gluc,u
- unbound metabolic clearance caused by the formation of repaglinide glucuronide
- CLmet,M2,u
- unbound metabolic clearance caused by the formation of M2
- LogD7.4
- distribution coefficient between octanol and water at pH 7.4
- CV
- coefficient of variation
- PBPK
- physiologically based pharmacokinetic
- DPBS
- Dulbecco's phosphate-buffered saline
- DMSO
- dimethyl sulfoxide
- LC
- liquid chromatography
- MS/MS
- tandem mass spectrometry
- HPLC
- high-performance liquid chromatography
- Scell
- total cell concentration
- Smed,u
- unbound media concentration
- rmse
- root mean square error
- gmfe
- geometric mean fold error.
- Received August 19, 2011.
- Accepted December 20, 2011.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|